These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 4809201)

  • 41. Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration, and alcoholic fatty liver.
    Barter PJ; Nestel PJ; Carroll KF
    Metabolism; 1972 Feb; 21(2):117-24. PubMed ID: 5009387
    [No Abstract]   [Full Text] [Related]  

  • 42. Long-term treatment of hyperlipidemic patients with clofibrate.
    Berkowitz D
    JAMA; 1971 Nov; 218(7):1002-5. PubMed ID: 5000568
    [No Abstract]   [Full Text] [Related]  

  • 43. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
    Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Type V hyperlipoproteinaemia. Metabolic changes in hyperlipaemic and previously hyperlipaemic ("susceptible") male patients.
    Jacobsen BB
    Atherosclerosis; 1973; 17(3):471-81. PubMed ID: 4577010
    [No Abstract]   [Full Text] [Related]  

  • 45. Influence of triglyceridemia level on glucose tolerance and insulinemia in subjects with type IV hyperlipoproteinemia.
    Debry G; Drouin P; Mejean L
    Horm Metab Res; 1974 Sep; 6(5):421-2. PubMed ID: 4425070
    [No Abstract]   [Full Text] [Related]  

  • 46. [Normal behavior of glucose tolerance, insulin secretion and free fatty acids under carbohydrate load in childhood].
    Amendt P; Michaelis D; Gottschling D; Hildmann W
    Endokrinologie; 1974 Sep; 63(3):373-80. PubMed ID: 4470085
    [No Abstract]   [Full Text] [Related]  

  • 47. Lipid, glucose, and insulin interrelationships in normal, prediabetic, and chemical diabetic subjects.
    Kyner JL; Levy RI; Soeldner JS; Gleason RE; Fredrickson DS
    J Lab Clin Med; 1976 Sep; 88(3):345-58. PubMed ID: 956689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Potentiation by clofibride of the heparin-induced clearing reaction (intravascular hydrolysis of neutral lipids), in hyperlipemic rabbits].
    Elsair J; Marquie G; Drif M; Khelfat K; Benouniche N; Tabet Aoul M; Tabet Aoul FS; Iklef F; Ghouini A
    C R Seances Soc Biol Fil; 1982; 176(2):140-5. PubMed ID: 6212098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Stimulation of insulin secretion and hypoglycemia by medium chain triglyceride].
    Ide H
    Nihon Naika Gakkai Zasshi; 1971 Feb; 60(2):115-24. PubMed ID: 5103075
    [No Abstract]   [Full Text] [Related]  

  • 50. [Hypertriglyceridemia induced by carbohydrates in primary hyperlipoproteinemia].
    Lussier-Cacan S; Beaudoin R; Gattereau A; Davignon J
    Union Med Can; 1977 Apr; 106(4):474-84. PubMed ID: 860339
    [No Abstract]   [Full Text] [Related]  

  • 51. [The lipid reducing action of phenformin in primary type IV hyperlipoproteinaemia (author's transl)].
    Lang PD; Vollmar J; Klemens UH; von Löwis P; Gries FA; Koschinsky T; Huth K; Pilz E; Schlierf G; Kremer GJ; Lenhart P; Schwandt P; Hammerl H; Studlar M
    Dtsch Med Wochenschr; 1973 Nov; 98(48):2280-6. PubMed ID: 4762828
    [No Abstract]   [Full Text] [Related]  

  • 52. [Incidence of hyperlipoproteinemia and other risk factors in chronic and acute phases of patients with myocardial infarct].
    Diehl HJ; Sorge F; Hoffmann H; Weidener J; Schloss W; Schwartzkopff W
    Arzneimittelforschung; 1972 Oct; 22(10):1815-8. PubMed ID: 4678571
    [No Abstract]   [Full Text] [Related]  

  • 53. The identification of risk factors in normal children in the development of arteriosclerosis.
    Drash A; Hengstenberg F
    Ann Clin Lab Sci (1971); 1972; 2(5):348-59. PubMed ID: 5082977
    [No Abstract]   [Full Text] [Related]  

  • 54. 24-hour patterns of blood sugar, plasma insulin and free fatty acids in patients with primary endogenous hyperlipoproteinemia on isocaloric diets containing 30, 40 and 79 cal% carbohydrates.
    Schellenberg B; Oster P; Vogel G; Heuck CC; Schlierf G
    Nutr Metab; 1979; 23(4):316-26. PubMed ID: 220571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.
    Wolfe BM; Kane JP; Havel RJ; Brewster HP
    J Clin Invest; 1973 Sep; 52(9):2146-59. PubMed ID: 4353773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A study of patients with atherosclerosis and renal disease with respect to lipoprotein types, fibrinolysis, and carbohydrate tolerance.
    Wardle EN; Menon IS; Anderson J
    Q J Med; 1972 Jan; 41(161):15-23. PubMed ID: 5070986
    [No Abstract]   [Full Text] [Related]  

  • 57. [Liver findings in primary hyperlipoproteinemia (HLP)].
    Renger F; Hanefeld M; Jaross W; Stötzner H; Kemmer C; Leonhardt W; Trübsbach A; Schentke KU
    Dtsch Z Verdau Stoffwechselkr; 1973; 33(4):199-203. PubMed ID: 4365203
    [No Abstract]   [Full Text] [Related]  

  • 58. [Drugs which influence plasma fatty acids and lipoproteins. Opinion of Prof. Rodolfo Paoletti].
    Salvati A
    Minerva Med; 1973 Sep; 64(62):3256-9. PubMed ID: 4359661
    [No Abstract]   [Full Text] [Related]  

  • 59. Carbohydrate metabolism in various types of hyperlipoproteinaemia.
    Romics L; Stützel M; Balázsi I; Varsányi-Nagy M
    Acta Med Acad Sci Hung; 1976; 33(3):225-32. PubMed ID: 1031550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insulin sensitivity after a reduced-fat diet and a monoene-enriched diet in subjects with elevated serum cholesterol and triglyceride concentrations.
    Louheranta AM; Schwab US; Sarkkinen ES; Voutilainen ET; Ebeling TM; Erkkilä AT; Turpeinen AK; Uusitupa MI
    Nutr Metab Cardiovasc Dis; 2000 Aug; 10(4):177-87. PubMed ID: 11079255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.